FDA appproves Somatuline Depot to treat Gastroenteropancreatic Neuroendocrine Tumors- Ipsen

Ipsen has announced that Somatuline Depot (lanreotide) Injection 120 mg was approved by the FDA for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).Pancreatic and gastrointestinal neuroendocrine tumors are rare cancers. There are an estimated 112,000 individuals currently living with pancreatic and gastrointestinal neuroendocrine tumors in the U.S., and the incidence and prevalence of this type of cancer have risen 4-to-6 fold in the last 30 years. Furthermore, up to ninety percent of patients are diagnosed at a late stage.